Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.

PLoS One · 2017 · PMC5516987 · PMID 28723914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Dalazatide treatment reduced IL-8 and IL-17A levels in the plasma of dalazatide-treated target lesion-responders, however, these changes did not reach statistical significance when compared to the treatment effect in the placebo and non-responder groups.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.